"Bristol Myers (BMY) has a partnership with Merck (NYSE:MRK) to jointly advance and promote Reblozyl after the latter company acquired its original developer, Acceleron Pharma, in November 2021.
The treatment is already indicated in the EU as a late-line option for adults with anemia due to MDS. If approved for the latest indication, it would represent the fourth authorized condition for the drug in the region.
The CHMP recommendation will next be reviewed by the European Commission (EC) before a final decision on marketing authorization."
https://seekingalpha.com/news/4070991-b ... l-reblozyl
Bristol Meyers MDS expansion labeling in Europe.....
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam